Essential Baseline Markers
Advanced peptide research requires comprehensive biomarker tracking beyond basic panels. Establish baseline values for IGF-1, IGFBP-3, cortisol, inflammatory markers (CRP, IL-6), metabolic parameters (glucose, HbA1c, lipid panel), and hormone profiles before initiating protocols.
Growth Hormone Pathway Monitoring
For GH-releasing peptides like CJC-1295 DAC or Ipamorelin, monitor IGF-1 levels every 2-4 weeks. IGF-1 peaks typically occur 7-14 days after protocol initiation. IGFBP-3 provides additional context for GH axis activity. Fasting glucose and HbA1c track metabolic effects.
Inflammatory Response Assessment
Peptides like BPC-157 and KPV target inflammatory pathways. Monitor high-sensitivity CRP, ESR, and pro-inflammatory cytokines (IL-1β, TNF-α) when available. These markers should trend downward with effective anti-inflammatory protocols. Track at baseline, 2 weeks, and 4-6 weeks.
Liver and Kidney Function
Comprehensive metabolic panels (CMP) monitor organ function during extended protocols. ALT, AST, and bilirubin assess liver health, while creatinine, BUN, and eGFR evaluate kidney function. Some peptides may affect protein metabolism, making these markers crucial.
Thyroid and Adrenal Assessment
TSH, T3, T4 monitoring detects thyroid axis changes with certain peptides. Cortisol (AM and PM) and DHEA-S track adrenal function. Growth hormone peptides can influence thyroid function over extended periods.
Timing and Frequency Guidelines
Baseline testing should occur 1-2 weeks before protocol initiation. Follow-up testing at 2-4 week intervals during active phases. Post-cycle testing 2-4 weeks after protocol completion assesses recovery and lingering effects.
This information is for research purposes only and does not constitute medical advice. Work with qualified healthcare providers for biomarker interpretation and safety monitoring.